HUMULIN 70/30
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HUMULIN 70/30 (HUMULIN 70/30).
Insulin replacement therapy. Human insulin is a recombinant DNA-derived polypeptide hormone that regulates glucose metabolism. Insulin binds to the insulin receptor, activating tyrosine kinase activity, which leads to increased glucose uptake in peripheral tissues (e.g., skeletal muscle, adipose tissue), inhibition of hepatic gluconeogenesis, and promotion of glycogen synthesis and lipogenesis.
| Metabolism | Insulin is degraded primarily in the liver, kidneys, and muscle tissue by insulin-degrading enzyme (IDE) and other proteolytic enzymes. |
| Excretion | Renal: 100% (metabolized to inactive fragments; negligible excretion of intact insulin). |
| Half-life | 0.5-1 hour (free insulin); 8-12 hours (prolonged due to NPH component, reflecting duration of action). |
| Protein binding | 10-20% (weakly bound to serum proteins; mainly albumin). |
| Volume of Distribution | 0.15-0.3 L/kg (approximates extracellular fluid volume). |
| Bioavailability | Subcutaneous: 60-80% (variable due to injection site, depth, and degradation). |
| Onset of Action | Subcutaneous: 30-60 minutes. |
| Duration of Action | Subcutaneous: 10-16 hours (biphasic: rapid-acting peak at 2-4 hours, intermediate peak at 4-8 hours). |
Subcutaneous injection, 0.5-1.0 units/kg/day divided into two doses (before breakfast and before dinner), adjusted based on blood glucose monitoring.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 25%; GFR 15-29 mL/min: reduce dose by 50%; GFR <15 mL/min: reduce dose by 50-75% and monitor glucose closely. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% and monitor for hypoglycemia. |
| Pediatric use | 0.5-1.0 units/kg/day subcutaneously in divided doses; for children <5 years, start at 0.5 units/kg/day; insulin-naive patients: 0.2-0.4 units/kg/day. |
| Geriatric use | Start at lower doses (0.2-0.5 units/kg/day) due to increased risk of hypoglycemia; titrate slowly with careful glucose monitoring. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HUMULIN 70/30 (HUMULIN 70/30).
| Breastfeeding | Insulin is endogenous and present in breast milk at low levels; exogenous insulin is not expected to affect the infant. Milk-to-plasma ratio is not established for this formulation, but endogenous insulin M/P ratio is approximately 1. Humulin 70/30 is considered compatible with breastfeeding; monitor infant for hypoglycemia if high doses used. |
| Teratogenic Risk | Insulin does not cross the placenta in significant amounts. Humulin 70/30 is not teratogenic; poor glycemic control increases risk of congenital anomalies. First trimester: risk of malformations linked to hyperglycemia, not insulin. Second and third trimesters: risk of macrosomia, neonatal hypoglycemia, and other complications if glycemic control is suboptimal. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to human insulin or any of its excipients","Hypoglycemic episodes"]
| Precautions | ["Hypoglycemia is the most common adverse effect; careful monitoring of blood glucose is required.","Changes in insulin strength, manufacturer, type, or method of administration may require dosage adjustment.","Hyperglycemia and ketoacidosis may occur if insulin doses are missed or inadequate.","Hypokalemia may occur due to shift of potassium into cells; monitor potassium levels in patients at risk.","Renal or hepatic impairment may alter insulin requirements.","Accidental mix-ups between insulin products have resulted in serious adverse events."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose and HbA1c frequently. Fetal monitoring: serial ultrasound for growth and amniotic fluid index; nonstress test or biophysical profile in third trimester if complications. Monitor for preeclampsia and gestational hypertension. |
| Fertility Effects | No direct adverse effects on fertility. Insulin is essential for metabolic homeostasis; poor glycemic control can impair fertility due to anovulation or menstrual irregularities. Humulin 70/30 does not independently affect fertility. |